KaloBios Pharmaceuticals has reported preliminary results of an ongoing multi-center Phase I study of KB004, an anti-EphA3 monoclonal antibody (mAb), which the company is developing as a treatment for hematologic malignancies. The experimental patient-targeted therapeutic has been well tolerated, with initial evidence of clinical activity. Forty-four patients with refractory disease or who were unfit for chemotherapy have been enrolled in the dose escalation portion of the study. Preliminary re...